1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
No deadline; program operates on a rolling application basis.
ReplenishRx is a program from Direct Relief that funds access to donated medications for uninsured and low-income patients at nonprofit health centers, free and charitable clinics, and charitable pharmacies.
The program provides a consistent supply of medicines donated by leading biotechnology, pharmaceutical, and healthcare companies, eliminating the need for individual patient assistance program applications and enabling faster access to needed treatments.
Eligible facilities must be registered nonprofits that provide health care regardless of patients' ability to pay — including Federally Qualified Health Centers and FQHC look-alikes — and must maintain proper drug dispensing controls, patient eligibility screening, and dispensing records retained for at least six years. Facilities must have a licensed medical director and consent to periodic program audits.
There is no specified cash award amount or application deadline.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
ReplenishRx | Direct Relief ReplenishRx provides an efficient and transparent model for uninsured, low-income patients to receive the medications they need from providers at nonprofit health centers, free and charitable clinics and charitable pharmacies.
The program ensures safety net providers have a consistent supply of medicines donated by leading biotechnology, pharmaceutical and healthcare companies for eligible patients, reducing the need to complete individual patient assistance program applications and enabling patients to receive the medicines they need without delay.
To participate, nonprofit clinics, charitable pharmacies and health centers must demonstrate required internal controls for drug dispensing and recordkeeping.
Criteria for Facility Participation Be registered as a nonprofit organization that provides health care to patients regardless of their ability to pay (e.g., free and charitable clinics, charitable pharmacies, Federally Qualified Health Centers (FQHCs), FQHC look-alikes, etc.) Maintain effective systems, policies and controls to: Comply with the rules and regulations for dispensing medications defined by the applicable state board of pharmacy Manage donated inventory through a physical or virtual process Perform and document patient eligibility screening and enrollment, as well as reverification of eligibility Retain patient eligibility and dispensing records for at least six years Ensure patients and insurers, such as Medicare and Medicaid, are not billed for donated products Adhere to all ReplenishRx requirements Have a medical director with a valid state license Consent to periodic program audits by Direct Relief To learn more or apply, fill out the form below.
This form needs Javascript to display, which your browser doesn't
According to the current listing, eligibility includes: Nonprofit health centers providing care regardless of patients' ability to pay; must have a licensed medical director, maintain proper inventory management, and retain records for at least six years. Confirm the full requirements in the official notice before applying.
ReplenishRx accepts applications on a rolling basis — there is no single fixed deadline. Check the official notice for any cycle-specific review dates.
ReplenishRx is funded by Direct Relief. Verify program details on the funder's official page before applying.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
PA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read articleDPA26BZ06-DV023 is a Direct-to-Phase-II SBIR paying $700,000 over 18 months plus a $500,000 option. The physics demands 256x more transmit power than the systems that qualify you to compete, and DARPA will not accept modeling alone as proof. Here is the eligibility wall, the five engineering problems, and who can realistically win it before the October 21 close.
Read articleOSW26BZ06-DV033 pays up to $1,500,000 over 24 months for agentic AI cognitive radar. But TS/SCI is gating, polygraphs must finish in 90 days, foreign nationals are barred even from unclassified work, and your feasibility evidence cannot come from prior SBIR funding. Here is how to read a security-gated SBIR before the October 21 deadline.
Read article